Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by stockman6767on Jan 09, 2015 1:04pm
334 Views
Post# 23302672

On HALO and IBB and PLI

On HALO and IBB and PLI
Agood example of what I posted yesterday. Compare today's chart for PLI to IBB - you will note they follow each other very well.

Another interesting thing to note about HALO and PLI is the following: We often speak of the orphan drugs trials as being largely derisked because they are (in most of these) jusrt fishing out particular proteins (oversimplified but basically true) and providing that protein to those who for some reason are defficient in that protein. So there is very little risk that the protein will not help to treat the disease caused bt the deficientcy. Halo now has a fairly similar notion of derisked trials in the  trials for pancreatic cancer and other high HA cancers. Basically they breakdown the HA matrix arounf the cancer cells and thus permit much greater access by the SOC chemo to work much more efficiently in the targeted neighborhood of the cancer cells. Here too, We already know that the SOC chemo works to some degree to kill the cancer cells, so there is not much risk to assume that given greater access to the cell by breaking down the HA matrix the the combined treatment will be better.

I hold a fair amount of HALO so my interest there is not just the connection to PLI, but that helps too as PLI is still my core holding.

Glta
Stockman6767
Bullboard Posts